On Tuesday, Nov. 6, Diplomat Pharmacy DPLO will release its latest earnings report. Benzinga's outlook for Diplomat Pharmacy is included in the following report.
Earnings and Revenue
Wall Street expects EPS of 22 cents and sales around $1.42 billion.
Diplomat Pharmacy reported a per-share profit of 25 cents when it published results during the same quarter last year. Sales in that period totaled $1.12 billion. If the company were to post earnings inline with the consensus estimate when it reports Tuesday, EPS would be down 12 percent. Revenue would be up 26.22 percent from the same quarter last year. Diplomat Pharmacy's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
| EPS Estimate | 0.23 | 0.22 | 0.16 | 0.15 |
| EPS Actual | 0.17 | 0.2 | 0.18 | 0.25 |
Stock Performance
Over the last 52-week period, shares are up 1.88 percent. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.
Analyst estimates have adjusted lower for EPS and revenues over the past 90 days. The most common rating by analysts on Diplomat Pharmacy stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
